| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $10.0M | -18.5% |
| SG&A Expense | $10.9M | -5.7% |
| Operating Income | -$20.9M | +12.3% |
| Pre-tax Income | -$19.5M | +10.8% |
| Net Income | -$19.5M | +10.8% |
| EPS (Basic) | -$33.06 | -2503.1% |
| EPS (Diluted) | -$33.06 | -2503.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.1M | +74.7% |
| Short-term Investments | $25.1M | -39.3% |
| Current Assets | $28.8M | -34.1% |
| Total Assets | $29.6M | -34.2% |
| Current Liabilities | $2.1M | +1.3% |
| Total Liabilities | $2.4M | -13.0% |
| Stockholders' Equity | $27.1M | -35.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$15.6M | +7.5% |
| Capital Expenditures | $5K | -86.5% |
| Investing Cash Flow | $15.9M | +1087.7% |
| Financing Cash Flow | $1.0M | -92.5% |
| Free Cash Flow | -$15.6M | +7.7% |